Vicore Pharma Holding Past Earnings Performance
Past criteria checks 0/6
Vicore Pharma Holding's earnings have been declining at an average annual rate of -15.8%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 98.2% per year.
Key information
-15.8%
Earnings growth rate
-2.1%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 98.2% |
| Return on equity | -52.0% |
| Net Margin | -188.5% |
| Next Earnings Update | 27 Feb 2025 |
Recent past performance updates
Recent updates
We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate
Sep 11
Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans
Feb 10We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully
Sep 21We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully
May 25Calculating The Intrinsic Value Of Vicore Pharma Holding AB (publ) (STO:VICO)
Jan 10Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?
Nov 13Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation
Jul 26Is Vicore Pharma Holding AB (publ) (STO:VICO) Worth kr17.6 Based On Its Intrinsic Value?
Mar 03What You Need To Know About Vicore Pharma Holding AB (publ)'s (STO:VICO) Investor Composition
Jan 11
Revenue & Expenses Breakdown
How Vicore Pharma Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 104 | -196 | 50 | 272 |
| 30 Jun 24 | 104 | -200 | 50 | 278 |
| 31 Mar 24 | 104 | -213 | 46 | 288 |
| 31 Dec 23 | 0 | -311 | 45 | 276 |
| 30 Sep 23 | 0 | -260 | 36 | 227 |
| 30 Jun 23 | 0 | -265 | 35 | 232 |
| 31 Mar 23 | 0 | -261 | 36 | 226 |
| 31 Dec 22 | 0 | -288 | 38 | 250 |
| 30 Sep 22 | 0 | -308 | 36 | 269 |
| 30 Jun 22 | 0 | -337 | 33 | 301 |
| 31 Mar 22 | 0 | -342 | 28 | 310 |
| 31 Dec 21 | 0 | -296 | 22 | 272 |
| 30 Sep 21 | 0 | -274 | 25 | 251 |
| 30 Jun 21 | 0 | -213 | 25 | 194 |
| 31 Mar 21 | 0 | -167 | 25 | 160 |
| 31 Dec 20 | 0 | -147 | 25 | 142 |
| 30 Sep 20 | 0 | -116 | 22 | 112 |
| 30 Jun 20 | 0 | -103 | 22 | 94 |
| 31 Mar 20 | 0 | -105 | 24 | 83 |
| 31 Dec 19 | 0 | -93 | 27 | 67 |
| 30 Sep 19 | 0 | -79 | 27 | 57 |
| 30 Jun 19 | 0 | -71 | 26 | 44 |
| 31 Mar 19 | 0 | -38 | 21 | 31 |
| 31 Dec 18 | 1 | -22 | 15 | 27 |
| 30 Sep 18 | -1 | -26 | 11 | 31 |
| 30 Jun 18 | 0 | -12 | 8 | 27 |
| 31 Mar 18 | 0 | -22 | 8 | 22 |
| 31 Dec 17 | 1 | -24 | 7 | 18 |
| 30 Sep 17 | 3 | -8 | 6 | 0 |
| 30 Jun 17 | 3 | -8 | 5 | 0 |
| 31 Mar 17 | 3 | -7 | 4 | 0 |
| 31 Dec 16 | 1 | -25 | 4 | 12 |
| 30 Sep 16 | 2 | -6 | 4 | 0 |
| 30 Jun 16 | 2 | -6 | 4 | 0 |
| 31 Mar 16 | 2 | -5 | 4 | 0 |
| 31 Dec 15 | 2 | -5 | 3 | 0 |
| 30 Sep 15 | 2 | 7 | 3 | 0 |
| 30 Jun 15 | 1 | 10 | 3 | 0 |
| 31 Mar 15 | 1 | 12 | 2 | 0 |
| 31 Dec 14 | 2 | 14 | 2 | 0 |
| 30 Sep 14 | 2 | 2 | 2 | 0 |
| 30 Jun 14 | 2 | 0 | 3 | 0 |
| 31 Mar 14 | 3 | -1 | 3 | 0 |
| 31 Dec 13 | 3 | -2 | 2 | 0 |
Quality Earnings: VICO is currently unprofitable.
Growing Profit Margin: VICO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VICO is unprofitable, and losses have increased over the past 5 years at a rate of 15.8% per year.
Accelerating Growth: Unable to compare VICO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VICO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Return on Equity
High ROE: VICO has a negative Return on Equity (-52.01%), as it is currently unprofitable.